Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26

Benzinga · 2d ago
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.